Agilent Technologies (NYSE:A)‘s stock had its “buy” rating reaffirmed by equities researchers at Robert W. Baird in a research note issued on Thursday, January 18th. They currently have a $76.00 target price on the medical research company’s stock. Robert W. Baird’s target price would indicate a potential upside of 13.47% from the stock’s current price.
A number of other equities analysts have also recently issued reports on A. Barclays increased their target price on Agilent Technologies from $67.00 to $71.00 and gave the stock an “overweight” rating in a report on Tuesday, November 21st. JPMorgan Chase & Co. raised their price target on Agilent Technologies to $75.00 and gave the company an “overweight” rating in a report on Tuesday, November 21st. Deutsche Bank set a $75.00 price objective on Agilent Technologies and gave the company a “buy” rating in a research report on Tuesday, November 21st. Cowen reiterated a “hold” rating and issued a $70.00 price objective on shares of Agilent Technologies in a research report on Wednesday, November 22nd. Finally, ValuEngine lowered Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $69.25.
Shares of Agilent Technologies (NYSE:A) traded up $1.93 during mid-day trading on Thursday, hitting $66.98. The company’s stock had a trading volume of 4,508,293 shares, compared to its average volume of 2,016,089. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.30 and a quick ratio of 2.85. Agilent Technologies has a 52 week low of $50.02 and a 52 week high of $75.00. The company has a market cap of $21,635.75, a P/E ratio of 31.90, a P/E/G ratio of 2.02 and a beta of 1.28.
Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Monday, November 20th. The medical research company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.05. Agilent Technologies had a return on equity of 16.95% and a net margin of 15.30%. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the company earned $0.59 EPS. The company’s quarterly revenue was up 7.0% on a year-over-year basis. equities analysts expect that Agilent Technologies will post 2.58 EPS for the current year.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 22,481 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $70.00, for a total transaction of $1,573,670.00. Following the transaction, the chief executive officer now owns 327,882 shares of the company’s stock, valued at $22,951,740. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Michael R. Mcmullen sold 21,850 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,638,750.00. Following the transaction, the chief executive officer now directly owns 324,687 shares in the company, valued at approximately $24,351,525. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 219,991 shares of company stock worth $15,468,795.
Several large investors have recently modified their holdings of A. Timber Hill LLC boosted its stake in shares of Agilent Technologies by 186.6% in the fourth quarter. Timber Hill LLC now owns 74,628 shares of the medical research company’s stock valued at $4,998,000 after buying an additional 48,586 shares during the period. Norinchukin Bank The boosted its stake in shares of Agilent Technologies by 7.6% in the fourth quarter. Norinchukin Bank The now owns 25,731 shares of the medical research company’s stock valued at $1,723,000 after buying an additional 1,814 shares during the period. ARP Americas LP acquired a new position in Agilent Technologies during the fourth quarter valued at approximately $569,000. Ontario Teachers Pension Plan Board raised its position in Agilent Technologies by 3.5% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 126,844 shares of the medical research company’s stock valued at $8,495,000 after purchasing an additional 4,231 shares in the last quarter. Finally, American International Group Inc. raised its position in Agilent Technologies by 8.9% during the fourth quarter. American International Group Inc. now owns 125,669 shares of the medical research company’s stock valued at $8,416,000 after purchasing an additional 10,264 shares in the last quarter.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.